多発性硬化症治療薬の世界市場：市場規模・シェア・動向分析 (薬剤クラス別・投与経路別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)

多発性硬化症治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の多発性硬化症治療薬の市場規模は、2025年から2030年にかけて5.93%のCAGRを記録し、2030年までに386億2,000万米ドルに達すると推定されています。

新興国市場における臨床上の高いアンメットニーズの存在は、多発性硬化症治療薬市場の最もインパクトのある促進要因の1つです。世界中の多くの組織が、進行性多発性硬化症やそれに関連する症状に関する認識を人々に広めることに積極的に関与しています。特筆すべき例としては、米国のNational Multiple Sclerosis Society（NMSS）、カナダのMultiple Sclerosis International Federation、European Multiple Sclerosis Platform（EMSP）、Multiple Sclerosis Society（MSC）などがあります。

償還プログラムも多発性硬化症治療薬の浸透を高めると予想されています。例えば、2014年6月、バイオジェン・アイデック・カナダ社は、MS治療薬TECFIDERAがB.C PharmaCareを通じて英国コロンビアで償還可能になったと発表しました。

最小限の投与量で費用対効果の高い新規治療薬の導入は、市場の成長をさらに促進すると予想されます。例えば、サノフィのLemtradaは、毎日投与が必要なCopaxoneと比較して、年3～5回の投与で済みます。

多発性硬化症治療薬市場：分析概要

• 薬剤クラス別では、免疫抑制剤が2024年の売上高シェア60.50%を占め、市場を独占しています。強力な薬剤パイプラインの存在と、今後6年以内に商業化が見込まれることが、市場成長を牽引すると期待されるいくつかの要因です。
• 投与経路別では、経口剤が予測期間中に最も速いCAGRで成長すると予想されます。
• 2024年、注射剤市場は52.50％の最大シェアを占めました。
• 2024年、北米が38.28%のシェアで世界市場を独占。多発性硬化症の有病率の増加、新薬のイントロダクション、米国におけるタイサブリやオーバージオなどの薬価の高さなどが、その優位性の要因となっています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 多発性硬化症治療薬市場：変動要因・傾向・範囲

• 市場の概要/連関の見通し
• 市場規模と成長見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 多発性硬化症治療薬市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 多発性硬化症治療薬市場：薬物クラス別の推定・動向分析

• セグメントダッシュボード
• 多発性硬化症治療薬市場：変動分析、薬物クラス別（2024年・2030年）
• 免疫抑制剤
• 免疫刺激剤

第5章 多発性硬化症治療薬市場：投与経路別の推定・動向分析

• セグメントダッシュボード
• 多発性硬化症治療薬市場：変動分析、投与経路別（2024年・2030年）
• 経口剤
• 注射剤
• その他

第6章 多発性硬化症治療薬市場：流通チャネル別の推定・動向分析

• セグメントダッシュボード
• 多発性硬化症治療薬市場：変動分析、流通チャネル別（2024年・2030年）
• 病院薬局
• 小売薬局
• eコマース

第7章 多発性硬化症治療薬市場：地域別の推定・動向分析

• 多発性硬化症治療薬の市場シェア：地域別（2024年・2030年）
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 最近の動向と影響分析：主要市場参入企業別
• 企業分類
• 企業ヒートマップ分析
• 企業プロファイル
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Biogen
  • Bayer AG
  • Sanofi
  • F. Hoffman-La Roche Ltd
  • Johnson &Johnson Services, Inc.
  • Merck &Co., Inc.
  • Takeda Pharmaceuticals Company Limited.
  • Horizon Therapeutics plc

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 4 Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 5 Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 6 North America Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 7 North America Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 8 North America Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 9 North America Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 10 U.S Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 11 U.S Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 12 U.S Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 Canada Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 14 Canada Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 15 Canada Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Mexico Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 17 Mexico Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 18 Mexico Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 19 Europe Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 20 Europe Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 21 Europe Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 22 Europe Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 23 UK Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 24 UK Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 25 UK Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 Germany Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 27 Germany Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million))
• Table 28 Germany Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 29 France Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 30 France Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 31 France Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Italy Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 33 Italy Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 34 Italy Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 35 Spain Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 36 Spain Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 37 Spain Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 Denmark Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 39 Denmark Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 40 Denmark Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 Sweden Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 42 Sweden Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 43 Sweden Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Norway Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 45 Norway Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 46 Norway Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 51 Japan Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 52 Japan Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 53 Japan Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 54 China Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 55 China Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 56 China Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 57 India Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 58 India Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 59 India Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 South Korea Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 61 South Korea Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 62 South Korea Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Australia Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 64 Australia Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 65 Australia Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 Thailand Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 67 Thailand Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 68 Thailand Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 69 Latin America Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 70 Latin America Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 71 Latin America Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 72 Latin America Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 Brazil Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 74 Brazil Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 75 Brazil Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Argentina Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 77 Argentina Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 78 Argentina Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 83 South Africa Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 84 South Africa Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 85 South Africa Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 86 UAE Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 87 UAE Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 88 UAE Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 89 Kuwait Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 90 Kuwait Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 91 Kuwait Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Multiple Sclerosis Therapeutics Market Segmentation
• Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 11 Penetration & Growth Prospect Mapping
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Multiple Sclerosis Therapeutics market: Drug Class outlook and key takeaways
• Fig. 15 Multiple Sclerosis Therapeutics market: Drug Class movement analysis & market share 2024 & 2030
• Fig. 16 Immunosuppressants market, 2018 - 2030 (USD Million)
• Fig. 17 Immunostimulants market, 2018 - 2030 (USD Million)
• Fig. 18 Multiple Sclerosis Therapeutics market: Route of Administration outlook and key takeaways
• Fig. 19 Multiple Sclerosis Therapeutics market: Route of Administration movement analysis & market share 2024 & 2030
• Fig. 20 Oral Multiple Sclerosis Therapeutics market, 2018 - 2030 (USD Million)
• Fig. 21 Injectable Multiple Sclerosis Therapeutics market, 2018 - 2030 (USD Million)
• Fig. 22 Others Multiple Sclerosis Therapeutics market, 2018 - 2030 (USD Million)
• Fig. 23 Multiple Sclerosis Therapeutics market: Distribution Channel outlook and key takeaways
• Fig. 24 Multiple Sclerosis Therapeutics market: Distribution Channel movement analysis & market share 2024 & 2030
• Fig. 25 Hospital Pharmacies, 2018 - 2030 (USD Million)
• Fig. 26 Retail Pharmacies, 2018 - 2030 (USD Million)
• Fig. 27 E-Commerce, 2018 - 2030 (USD Million)
• Fig. 28 Regional Marketplace: Key Takeaways
• Fig. 29 Regional Outlook, 2024 & 2030
• Fig. 30 Regional Market Dashboard
• Fig. 31 Regional Market Place: Key Takeaways
• Fig. 32 North America
• Fig. 33 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 34 U.S. Key Country Dynamics
• Fig. 35 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 36 Canada Key Country Dynamics
• Fig. 37 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 38 Mexico Key Country Dynamics
• Fig. 39 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 40 Europe
• Fig. 41 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 42 UK Key Country Dynamics
• Fig. 43 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 44 Germany Key Country Dynamics
• Fig. 45 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 46 France Key Country Dynamics
• Fig. 47 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 48 Italy Key Country Dynamics
• Fig. 49 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 50 Spain Key Country Dynamics
• Fig. 51 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 52 Denmark Key Country Dynamics
• Fig. 53 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 54 Sweden Key Country Dynamics
• Fig. 55 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 56 Norway Key Country Dynamics
• Fig. 57 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 58 Asia Pacific
• Fig. 59 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 60 Japan Key Country Dynamics
• Fig. 61 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 62 China Key Country Dynamics
• Fig. 63 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 64 India Key Country Dynamics
• Fig. 65 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 66 Australia Key Country Dynamics
• Fig. 67 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 68 Thailand Key Country Dynamics
• Fig. 69 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 70 South Korea Key Country Dynamics
• Fig. 71 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 72 Latin America
• Fig. 73 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 74 Brazil Key Country Dynamics
• Fig. 75 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 76 Argentina Key Country Dynamics
• Fig. 77 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 78 MEA
• Fig. 79 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 80 South Africa Key Country Dynamics
• Fig. 81 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 82 Saudi Arabia Key Country Dynamics
• Fig. 83 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 84 UAE Key Country Dynamics
• Fig. 85 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 86 Kuwait Key Country Dynamics
• Fig. 87 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 88 Strategy Mapping

Multiple Sclerosis Therapeutic Market Growth & Trends:

The global multiple sclerosis therapeutic market size is estimated to reach USD 38.62 billion by 2030, registering a CAGR of 5.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. The presence of high unmet clinical needs in developing regions is one of the highest impact rendering drivers of the multiple sclerosis therapeutics market. Many organizations over the globe are actively involved in spreading awareness among people regarding progressive multiple sclerosis and the symptoms associated with it. Some notable examples include the National Multiple Sclerosis Society (NMSS) in the U.S., Multiple Sclerosis International Federation in Canada, European Multiple Sclerosis Platform (EMSP), and the Multiple Sclerosis Society (MSC).

Reimbursement programs are also anticipated to enhance the penetration of multiple sclerosis drugs. For instance, In June 2014, Biogen Idec Canada, announced that its TECFIDERA drug for the treatment of MS is available for reimbursement in British Colombia through B.C PharmaCare.

The introduction of novel therapeutics with minimal dosage requirement and cost-effectiveness is further expected to favor market growth. For, instance Lemtrada by Sanofi needs to be administered 3-5 times per year as compared to Copaxone, which requires daily administration.

Multiple Sclerosis Therapeutic Market Report Highlights:

• Based on drug class, the immunosuppressant segment dominated the market with the largest revenue share of 60.50% in 2024. The presence of a strong drug pipeline and its expected commercialization in the coming six years are some factors expected to drive market growth.
• Based on route of administration, the oral segment is expected to grow at the fastest CAGR rate over the forecast period, propelled by increasing patient preference for convenient, home-based treatment options.
• In 2024, the injectable market held the largest share of 52.50% in 2024, owing to high prescription rates & price.
• North America dominated the global market with a share of 38.28% in 2024. The increasing prevalence of multiple sclerosis, the introduction of new drugs, and high prices of drugs, such as Tysabri and Aubagio in the U.S., are some factors responsible for its dominance.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Multiple Sclerosis Therapeutics Market Variables, Trends & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Multiple Sclerosis Therapeutic Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape
  • 3.4.3. Pipeline Analysis, By Phase

Chapter 4. Multiple Sclerosis Therapeutics Market: Drug Class Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Multiple Sclerosis Therapeutic Market: Drug Class Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Immunosuppressants
  • 4.3.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Immunostimulants
  • 4.4.1. Immunostimulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Multiple Sclerosis Therapeutics Market: Route of Administration Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Multiple Sclerosis Therapeutic Market: Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Oral
  • 5.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Injectable
  • 5.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Multiple Sclerosis Therapeutics Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Multiple Sclerosis Therapeutic Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. Hospital Pharmacies
  • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Retail Pharmacies
  • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. E-Commerce
  • 6.5.1. E-Commerce Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Multiple Sclerosis Therapeutic Market: Regional Estimates & Trend Analysis

• 7.1. Multiple Sclerosis Therapeutic Market Share, By Region, 2024 & 2030 (USD Million)
• 7.2. North America
  • 7.2.1. North America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. France Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Norway Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. China
    • 7.4.2.1. China Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Japan Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. India Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Australia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Thailand Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. UAE Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Teva Pharmaceutical Industries Ltd.
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. Pfizer Inc.
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. Biogen
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. Bayer AG
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. Sanofi
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. F. Hoffman-La Roche Ltd
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. Johnson & Johnson Services, Inc.
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. Merck & Co., Inc.
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. Takeda Pharmaceuticals Company Limited.
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives
  • 8.4.10. Horizon Therapeutics plc
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/ Strategic Initiatives